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INTRODUCTION 
Injection of local anaestheic into the epidural space to produce 
reversible loss of all modalities of sensations as well as  motor functions   
is termed as epidural anaesthesia. Although techniques of epidural 
anaesthesia do not offer the economy of drug dosage or degrees of 
blockade of spinal anaesthesia, they have an added advantage of 
continuing post operative analgesia through the catheter in the epidural 
space.  
Epidural anaesthesia is  more versatile and is being used 
extensively in fields of surgical anaesthesia, obstretic analgesia , 
management of acute or chronic pain          
Since 1940’s when epidural neuraxial blockade was first 
described studies have been extensively conducted to identify an ideal 
adjuvant for epidural anaesthesia along with the local anaesthetic . As 
epidural neuraxial blockade requires large volume local  anaesthetic  
attempts are being made  to identify an adjuvant which would decrease 
the requirement of local anaesthetic, fasten the onset of action of local 
anaesthetic, produce sedation,maintain hemodynamic stability and 
prolong the duration of sensory blockade. 
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Opioids are being traditionally used as adjuvants in epidural 
neuraxial blockade as they produce sedation and have inherent analgesic 
activity. Recently α2 agonist like  dexmedetomidine and clonidine are 
being studied as they have most of the desirable qualities of an ideal 
adjuvant. 
Buprenorphine is a long acting agonist anatagonist opioid with 
high affinity to µ receptors and 33 times more potent than morphine
2
 
can be used as an adjuvant in epidural anaesthesia. 
Dexmedetomidine, a highly selectively α2A agonist which 
produces both sedation and augments the analgesic action of local 
anaesthetic
2
when it is given epidurally. 
Keeping in mind the pharmacological interactions and adverse 
effects of Buprenorphine and Dexmedetomidine, we planned to conduct 
a double blinded prospective randomized control study in patients 
undergoing lower limb orthopaedic surgeries under epidural anaesthesia. 
We used 0.5% bupivacaine and either one of the above two drugs 
epidurally with an aim of comparing the perioperative analgesic 
efficacy, sedation and hemodynamic stability of these 2 drugs given 
epidurally 
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EPIDURAL ANAESTHESIA 
ANATOMY OF EPIDURAL SPACE : 
The epidural space is a saw tooth shaped space extending from 
the base of skull to Sacro-Coccygeal membrane and has direct 
communications with paravertebral space and indirect communications 
with the CSF. Epidural space is not as voluminous as subarachanoid 
space. 
BOUNDARIES OF EPIDURAL SPACE
1
: 
Superiorly - Foramen magnum. 
Inferiorly - Sacral hiatus and sacrococcygeal membrane. 
Laterally - Periosteum of pedicles of vertebrae and inter 
vertebral foramen. 
Anteriorly - Posterior longitudinal ligament covering 
vertebral bodies and intervertebral discs. 
Posterior - Periosteum of anterior surfaces of 
lamina.articular process and connecting 
ligaments and interlaminar spaces filled by the 
ligamentum flavum. 
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CONTENTS OF EPIDURAL SPACE: 
It is a potential space filled with epidural pad of fat, areolar 
tissues, lymphatics, epidural plexus of  veins  (Batson’s plexus), nerve 
roots that traverse it . Of prime importance are the epidural pad of fat 
and venous plexus. It is postulated that volume of fat in the epidural 
space explain the age related changes in epidural dose requirement. 
Obese individuals have more fat, as age increases the volume of fat 
decreases . 
Large valveless epidural veins are part of internal vertebral 
venous plexus. These plexus have rich segmental connections at all 
levels. Within intervertebral foramina and epidural space by the way of 
intervertebral foramina epidural venous plexus communicate with 
thoracic and abdominal veins. So any pressure change in these cavities 
are transmitted to the epidural veins. Therefore in conditions like, 
pregnancy, vena caval obstructions, caution must be taken during 
epidural neuraxial blockade . 
Important aspects that should  be taken  care are
1
 
1. Epidural needle insertion must be in midline to avoid large 
laterally placed epidural veins. 
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2. Insertion of epidural needle or catheter should not be done during 
episodes of marked increase in size of epidural veins such as with 
increased thoraco-abdominal pressure during straining in case of 
labor analgesia. 
3. Presence of vena caval obstruction calls for a reduction in dose, 
decreased rate of injection and increased care during aspiration. 
A unique feature of epidural veins that is  of importance is, 
draining of CSF and transfer of local anaesthetic to CSF through regions 
of dural cuffs where the subarchanoid space invaginates the epidural 
veins. 
STRUCTURES PIERCED DURING EPIDURAL NEEDLE 
INSERTION
1
  : 
 Skin 
 Subcutaneous tissue. 
 Suprapinous ligament. 
 Interspinous ligament. 
 Ligamentumflavum. 
 Epidural space. 
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PHYSIOLOGY OF  EPIDURAL NEURAXIAL BLOCKADE : 
The site of action of local anaesthetic is the spinal nerve roots. 
Lumbar segmental nerve roots are mixed nerves that contain, 
autonomic, somato sensory and motor nerve fibres. 
 Pre ganglionic Sympathetic efferent blockade of (T1 - L2) 
segments leads to peripheral vasodilation. 
 Sensory blockade - afferent blockade of both somatic and 
visceral pain stimuli. 
 Motor blockade - efferent blockade leading to varying 
degrees of motor paralysis and reflex muscle relaxation 
without paralysis due to ‘deafferentation.’ 
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Injection site of epidural anaesthetic must be close to the desired 
nerve roots to be blocked to reduce the volume of local anaesthetic 
required and to reduce complications of systemic absorption. 
Differential neural blockade which is a feature of subarachanoid 
blockade is also seen in epidural blockade , this means different types of 
nerve fibres differ in their sensitivity to the local anaesthetic. 
Pre ganglionic Sympathetic fibres are usually blocked first 
followed by pain/temperature, followed by motor blockade. 
Autonomic block is of one or two segments higher than sensory 
blockade which is one or two segments higher than that of  motor 
blockade. 
Physiologic effects of epidural blockade depend upon the spinal 
level and number of segment to be blocked. High thoracic and extensive 
epidural blocks produce profound sympathetic blockade. Usually, 
lumbar epidural blockade does not produce extensive neuraxial 
blockade and profound physlogic effect on the cardiovascular system. 
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PHARMACOLOGY OF EPIDURAL BLOCKADE: 
  For a successful epidural blockade, the anaesthesiologist should 
understand the physiology of nerve conduction and pharmacology of 
local anaesthetics. 
The number of segments to be blocked should be calculated and 
the tip of the epidural catheter should be placed in such a way that it 
could cover all  the required segments with optimal volume of drug. 
Potency, duration of action of the drug and its ability to 
preferentially block different types of nerve fibers should also be taken 
into consideration. 
MECHANISM OF ACTION OF LOCAL ANESTHETIC: 
Local anaesthetics bind to the sodium channel in the nerve fibres 
in the active state and blocks the activation of sodium channel. Thus 
preventing the movement of sodium ions. This blocks the generation of 
Action potential  known as membrane stabilization effect (i.e.) further 
nerve stimulation will not affect the resting membrane potential. 
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SPECIFIC TO EPIDURAL SPACE: 
 Sensory block due to blockade of Na+ channels in dorsal horn and 
motor block due to blockade of Na
+
& K
+
 ion channels in ventral 
horn. 
 In addition they also block release of substance P which is 
involved in pain signal processing.  
 Blockade of the voltage gated Ca++ channel pre synaptic level is  
responsible for indirect action of centrally administered local 
anaesthetics which blocks the release of neurotransmitters like 
glutamate substance P, calcitonin gene related peptide, neurokinin 
1,2 (NK1, NK2) 
FACTORS AFFECTING EPIDURAL BLOCKADE : 
1. Site of injection. 
2.  Size of Nerve root. 
3. Posture-  sitting -minimally lateral - definitely 
4. Drug used( long acting /short acting) 
5. Dose (volume / concentration) 
6. Addition of epinephrine. 
10 
 
7. Number & frequency of injection. 
8. Speed of injection 
 
EPIDURAL EQUIPMENTS
3
: 
Epidural needles :Tuohy’s , Crawford  needle . 
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Epidural catheters:  
Open tip closed, closed tip with single lateral port, closed tip with 
3 radially arranged ports. 
 
RECENT ADVANCE  : 
Ultrasonography and Epiduroscope have been recently 
introduced in the armamentarium to identify epidural space. 
Epiduroscope plays a major role in percutaneous epidural 
neurolysis in chronic pain management. 
12 
 
 
 
 
 TECHNIQUE 
1. Midline approach 
2. Paraspinous approach 
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Positioning : 
 
INDICATIONS: 
1) Surgery 
a. Upper & lower abdominal surgery for intra and 
postoperative  pain management  
b. Urological surgeries 
c. Thoracic surgeries. 
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2) Postoperative and post trauma pain relief. 
3) Obstetric  anesthesia and analgesia. 
4) Diagnosis and management of chronic pain. 
5) Epidural steroids and narcotics 
6) Newer techniques - Epidural electrical stimulation. 
CONTRA INDICATIONS: 
Absolute: 
 Patient refusal. 
 Major coagulation disorders. 
 Uncorrected hypovolemia. 
 Infection at site of injection. 
 Severe sepsis. 
Relative: 
 Pre-existing neurological deficit. 
 Spine deformities. 
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COMPLICATIONS: 
1. Director trauma to nerve and nerve roots. 
2. Epidural hematoma 
3. Abscess 
4. Neurotoxicity 
5. Anterior spinal artery spasm due to needle injury or by use of 
epinephrine. 
6. Missed segments - patching uptake of blockade. 
7. Inadequate motor block  
8. Sacral sparing. 
9. Inadvertent dural puncture 
10. Subdural communication 
11. Cannulation into an epidural vein. 
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PHARMACOLOGY OF  BUPIVACAINE
 
STRUCTURE
2
  : 
 
CHEMICAL COMPOSITION : 
Bupivacaine Hydrochlorideis an amide group of local 
anaesthetic2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-
mono-hydrochloride  and is formed by addition of a butyl group to the 
piperidine nitrogen of Mepivacaine making it 35 times more potent. 
Local anesthetics prevent transmission of nerve impulses (conduction 
blockade) by inhibiting the passage of sodium ions through selective 
sodium channels in nerve membranes. However, they do not alter the 
resting membrane potential or threshold potential. 
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MECHANISM OF ACTION : 
Bupivacaine binds to alpha subunit of the sodium channel 
 
Sodium channels exist in activated-open,  
inactivated-closed and resting-closed. 
 
Bupivacaine selectively binds to sodium channels in 
inactivated-closed 
 
Prevent their change to rested-closed, activated-open states. 
 
Sodium channels are not permeable in inactivated-closed state 
 
No conduction of impulses and No action potential occurs 
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Frequency dependent blockade : 
 Sodium ion channels tend to recover from local anesthetics 
induced conduction blockade between action potentials and to develop 
additional conductional blockade. Local anesthetics gain access to 
receptors only when sodium channels are in activated-open states. So, a 
resting nerve is less sensitive to conduction blockade than a repetitively 
stimulated nerve. 
Other Sites Of Action : 
 In addition to sodium channels bupivacaine blocks voltage 
dependent potassium ion channels. This explains the reason for 
broadening of action potential. Bupivacaine also blocks the calcium ion 
channels (L-type). Bupivacaine blocks both types of pain fibres, 
myelinated A-delta and unmyelinated C-fibres. Preganglionic-B fibres 
are readily blocked by local anesthetics than the other two nerve fibres. 
PHARMACOKINETICS: 
Bupivacaine is a weak base that has a pKa value above the 
physiological pH. Hence only less amount of the drug is in non-ionised 
form. Acidosis increases the pH of the medium increasing the ionised 
19 
 
fraction of the  drug resulting in poor quality of anaesthesia. Absorption 
of the drug depends on site of injection, its dosage, adjuvants such as 
epinephrine, opioids, and the pharmacological characteristics of the 
drug. The plasma concentration is determined by the rate of tissue 
distribution and rate of clearance. The lungs are capable of extraction of 
bupivacaine from the systemic circulation and its first pass pulmonary 
extraction is dose dependent. Bupivacaine binds to the plasma protein 
alpha-1 acid glycoprotein.  
Metabolism : 
Bupivacaine Hydrochloride is metabolised primarily in the liver. 
It undergoes aromatic hydroxylation, N-dealkylation, amide hydrolysis 
and conjugation with glucuronic acid. Patients with hepatic disease may 
be more susceptible to the toxicities of the amide-type local anesthetics. 
Pipecoloxylidine is the major metabolite of Bupivacaine Hydrochloride. 
Only 6% of Bupivacaine is excreted unchanged in the urine.  
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Onset Slow 
Duration of action 240-480 mins 
pK 8.1 
Protein binding  95% 
Lipid solubility 1 
Volume of distribution 73 litres 
Clearance 0.47 litres/min 
Elimination half time 210 mins 
 
USES:  
Regional Anaesthesia – (i) Local infiltration (ii) Peripheral nerve block 
(iii) Epidural anesthesia(iv) Spinal anesthesia (v) topical anaesthesia.  
Concentration Used Maximum Permitted  Dose 
0.125%-0.5% (preservative) 3mg/ kg body weight 
0.75% ( not to be used in obstretic 
epidurals) 
Max. over 4 hrs-150mg 
Max. During 24 hrs-400 mg 
0.5% plain/hyperbaric solution 
(intrathecal use) 
20 mg 
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SIDE EFFECTS: 
a. Allergic reactions 
b.  Neurotoxicity – tinnitus , vertigo , muscle twitches , slurred 
speech and seizures. 
c.  Cardiotoxicity – precipitous hypotension, cardiac dysrhythmias 
and atrioventricular blocks. 
d.  Hepatotoxicity 
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PHARMACOLOGY  OF  DEXMEDETOMIDINE 
STRUCTURE 
2
: 
 
CHEMICAL COMPOSITION : 
Imidazole derivative, Active s-Enantiomer of Meditomidine (+)-
4-(S)-[1-(2, 3-dimethylphenyl) ethyl]- 1H-imidazole 
monohydrochloride. It is a highly selective α2a agonist   (α2 :α1   =  
1600:1) 
MECHANISM OF ACTION : 
Specific alpha 2 adrenoceptoragonist, acts through post synaptic 
α2 receptors by increasing conductance through potassium channels  
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PHARMACOKINETICS : 
             95% protein bound with a volume of distribution 1.5 L/kg.with 
at1/2α ( rapid distribution) of 6 minutes and t1/2β (elimination half life ) 
of  2-3 hours. 
METABOLISM : 
By Conjugation (41%) and N-methylation(21%).Inactive 
metabolites excreted in urine and faeces. 
PHARMACODYNAMICS : 
Central nervous system : 
Unique sedative property, patients will be sedated but arousable 
without respiratory depression . 
Cardiovascular system  : 
             Reduces HR and SVR. There is a biphasic response on blood 
pressure. 
Respiratory system : 
Reduces minute ventilation, retains response  to hypercarbia 
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ROUTES OF ADMINISTRATION : 
Intravenous, Intramuscular, Epidural, Intrathecal, Intranasal 
DOSE  : 
Loading dose  : 0.5-1.0µg/kg over 10 minutes.  
          Maintenance dose :  0.3-0.7µg/kg/hr not exceeding 24 hours  
CONTRAINDICATIONS : 
Known hypersensitivity to the drug  
USES : 
1. ICU sedation in mechanically ventilated patients 
2. In anaesthesia 
a.  before induction-at a dose of 0.3-0.67µg/kg given before 
10-15 minutes attenuates the hemodynamic response to 
intubation   
b. as a premedication 2.5µg/kg 
c.  sedation during regional anaesthesia 
d.  as an adjuvant  in bariatric surgery, craniotomy aneurysm, 
sleep  apnea patient. 
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3. Procedural sedation : 
a. for securing the airway during  awake fibreoptic intubation. 
b. for bronchoscopy  
ADVERSE EFFECTS : 
Most common are  
a. Hypotension 
b. Bradycardia 
c. Dry Mouth 
d. Hypertension 
e. Arrythmias 
f.  AV  block 
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ALPHA 2 ANTAGONIST : 
Atipamezole: 
Scheinin et al. reported about the ability of atipamezole, a novel 
selective α2-adrenoceptor antagonist, to reverse the sedative properties 
of  intramuscular dexmedetomidine were  dose-dependently antagonized 
by intravenous atipamezole. However, the sensitivity for reversal of 
these two responses may be different.Because the agonist and the 
antagonist have similar elimination half-lives, the likelihood of 
recurrence of the clinical effects of dexmedetomidine after reversal 
byatipamezole is small. Therefore the alpha 2 agonists providea 
titratable form of hypnotic sedation that can be reversed readily. 
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PHARMACOLOGY OF BUPRENORPHINE 
STRUCTURE
2
 : 
 
CHEMICAL COMPOSITION : 
Synthetic derivative of thebaine 
MECHANISM OF ACTION : 
Partial agonist at  µ receptor and dissociates very slowly leading 
to prolonged duration of analgesia,also has high affinity to kappa 
receptor but less intrinsic activity . 
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DOSE: 
Intravenous, Intramuscular  0.3 – 0.6 mg,  8th hourly  
Sublingual  0.2 -0.4 mg,  8
th
   hourly  
Epidural  upto 0.3 mg 
Intrathecal  0.15 mg 
PHARMACOKINETICS : 
Drug undergoes significant first pass metabolism when given 
orally so sublingual route is preferred, bioavailability is 40-90% when 
given intramuscular.Volume of distribution is 3.2 L/kg, 90% protein 
bound 
Metabolism : 
Undergoes hepatic metabolism by dealkylation and conjugation to 
glucuronides which are lipid soluble and excreted in bile. Elimination 
half life is 5 hours  
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PHARMACODYNAMICS : 
Cardiovascular system : 
Minimal effects on CVS   reduces heart rate by less than 25%, 
systolic blood pressure may fall by 10%  
Central nervous system : 
Nearly 33 times more potent than morphine. Produces meiosis 
and analgesia as like other opioids, reduces cerebral glucose 
metabolism, reduces gastric motility and has emetic effect. 
Respiratory system : 
Produces respiratory depression and increases the threshold for 
hypercapneic ventilator drive. Has a ceiling effect. 
ADVERSE EFFECTS: 
 Drowsiness 
 Confusion 
 Nausea, vomiting 
 Headache 
 Pruritis 
 Urinary retention. 
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OPIOID ANTAGONIST : 
 Naloxone  
 Naltrexone 
 Nalmefene 
They are pure µ receptor antagonist with no agonist activity. 
Naloxone,the  most commonly used opioid antagonist could not 
be used to reverse all the effects of Buprenorphine as it is a partial 
agonist. 
Naloxone, at a dose of  1-4µg/kg i.v usually reverses opioid 
induced  analgesia and respiratory depression but due to its shorter 
duration of action a continuous infusion at the rate 5 µg/kg/hr is 
recommended.  
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REVIEW OF LITERATURE 
Sukhminder Jitsingh Bajua et al.,
4
(2011) studied the efficacy of 
epidural dexmedetomidine and fentanyl when combined with 
ropivacaine. 100 patients of age group 21-56 years and ASA physical 
status I & II who underwent lower limb orthopaedic surgeries were 
randomly allocated in 2 groups RD and RF groups  
RD -  Ropivacaine (15ml of 0.75%) + Dexmedetomidine(1 µg/kg) 
RF-Ropivacaine(15ml of 0.75%)  + Fentanyl (1 µg/kg) 
  Routine cardio-pulmonary monitoring parameters like NIBP, 
SPO2,ECG were recorded. Both groups were compared based on various 
block characteristics time to onset of analgesia at T10, maximum 
sensory analgesic level, time to max sensory blockade, time to two 
segmental regression and  sedation scores.  
Demographic profile of patients were comparable. Onset of 
analgesia, complete motor blockade and duration of post operative of 
analgesic were prolonged significantly in RD groups. Sedation scores 
were better with RD. Incidence of nausea and vomiting was 
significantly higher in RF group. 
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Consumption of local anesthetic for post operative analgesia was 
significantly low and RD group. To conclude demexdetomidine is a 
better adjuvant for epidural neuraxial blockade than  fentanyl at a dose 
of 1 µg/kg. 
Sukwinder Kaur Bajua et al.,
5 
(2011) did a comparative 
evaluation of epidural dexmedetomidine and clonidine in patients 
undergoing vaginal hysterectomies.50 patients undergoing vaginal 
hsytrectomies were randomly allocated in 2 groups : RD   andRC. 
RD -  Ropivacaine (17 ml of 0.75%) + Dexmedetomidine(1.5 µg/kg) 
RC-  Ropivacaine (17 ml of 0.75%) +  Clonidine (2 µg/kg) 
Onset of analgesia, sensory and motor blockade, sedation level, 
duration of analgesia and adverse effects were compared. Demographic 
profile, initial and postoperative block variables and cardio pulmonary 
parameters were comparable not significant in both groups. Whereas 
sedation was better in RD group and incidence of side effects was less in 
RD group. 
Sandip Sinha et al.,
6 
(2012) did a comparative study of analgesic 
efficacy of plain Ropivacaine vs Ropivacaine with Dexmedetomidine in 
Paravertebral block for unilateral renal study. 
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60 patients of ASA I & II undergoing unilateral renal surgery 
were allocated into 2 groups Group I - only Ropivacaine, Group II - 
Ropivacaine + Dexmedetomidine  (1 µg/kg) 
After administration of GA, parevertebral catheter was placed and 
block given with only. 0.25% Ropivacaine 18ml in group I and 0.25% 
Ropivacaine18ml + Dexmedetomidine 1µg/kg in group II. Postoperative 
pain relief was compared after extubation  by using VAS scale. 
Mean duration of analgesia was longer in Group II & total 
consumption of Ropivacaine was less in Group II. Addition of 
Dexmedetomidine to Ropivacaine significantly prolongs duration of 
Analgesia in Paravertebral block. 
Kiran agarwal et al.,
7
(2010) compared the analgesic efficacy of 
buprenorphine vs  clonidine with bupivacaine in lower segment 
caesarean section.  
112 female patients undergoing LSCS were allocated to 3 groups. 
a)  0.125%Bupivacaine + Buprenorphine (0.075mg) 
b)  0.125% Bupivacaine + Clonidine (37.5mg) 
c)  0.125% Bupivacaine  plain  were administered epidurally. 
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and  quality of  postoperative  pain relief was compared using 
VAS scale. 
Mean duration of analgesia was significantly more in 
Buprenorphine group. 
There was no respiratory depression in all 3 groups, Hypotension, 
Sedation were comparable in both Group I, II  and less in group III. 
Epidural buprenorphine produces prolonged postoperative 
analgesia and is safe in LSCS patients. 
Egon Lanz et al.,
8
(1984) did a double blind study comparing 
different doses of Epidural Buprenorphine 158 patients were allocated 
into 3 groups and were given either 0.15 mg epidural. Buprenorphine, 
0.3 mg in 15ml saline after 2% Mepivecaineanaesthesia, 0.3 mg 
Buprenorphine after 0.5% Bupivacaine and control group. 
The need for additional analgesics as well as side effect were 
observed. Analgesia after 150mg of Buprenorphine was superior to no 
reinjection (control group) after 6 hrs of surgery. 300mg of 
Buprenorphine was superior to both groups until twelfth hour. There 
was increase in PaCO2 2-5 mm of Hg between 2-4 hrs after 
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administration  0.3 mg of Buprenorphine. There was no evidence of 
respiratory depression. Other side effects were comparable in all groups. 
They concluded 300 micrograms of Epidural Buprenorphine 
could be given safely for postoperative analgesia following lower limb 
orthopaedicsurgeries. 
Sara Korula et al.,
9
(2010)compared epidural and intrathecal 
Buprenorphine using combined spinal epidural technique for caesarean 
section. 
90 patients undergoing LSCS (elective) of ASA I physical status 
were allocated into 3 groups to evaluate the analgesic effect of neurexial 
buprenorphine. 
Group I  - 150 µg  Buprenorphine intrathecally. 
Group II  - 150 µg  Buprenorphine epidurally. 
Group III  - 300 µg  Buprenorphine epidurally. 
They observed the following results. 
Group I  and Group III  had much longer duration of Analgesia 
than group II. 
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Group III had similar postoperative duration of analgesia as 
Group I without compromising patient safety and neonatal outcome with 
less side effect than Group I. Thus, they concluded that 300µg of  
Buprenorphine epidurally is equianalgesic to 150µg of intrathecally. 
Vijay G. Anand et al.,
10
(2011) compared the effects of caudal 
Dexmedetomidine  combined with Ropivacaine in children undergoing 
lower abdominal surgeries. 
60 children were allocated into 2 groups. 
Group RD - 2 µg/kg Dexmedetomidine + 1ml/kg of 0.25% Ropivacaine. 
Group R- 1 ml/kg of 0.25% Ropivacaine. 
Inhalational induction was done with O2: N2O , 1:1 and 8% 
Sevoflurane. After LMA insertion caudal block was given with the 
study drugs. Duration of postoperative analgesia was noted. It was 
significantly high in RD group. 
Intraoperative and postoperative hemodynamics were stable in 
both groups. They concluded that caudal Dexmedetomidine2 µg/kg with 
0.25%Ropivacaine 1ml/kg for lower abdominal surgeries resulted in 
better quality of analgesia, induced sleep and less side effects. 
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Rajni Gupta et al.,
11
(2011) compared intrathecal 
Dexmedetomidine and fentanyl as adjuvants to Bupivacaine in 60 
patients undergoing lower abdominal surgeries, they were allocated into 
2 groups and received either 12.5mg hyperbaric bupivacaine + 
5µgdexmedetomidine (group D) . 12.5 mg Hyperbaricbupivacaine + 
25µg of fentanyl (group F) . They observed that patient in group D had 
longer sensory and motor blockade and reduced demand for rescue 
analgesia for 24 hours. 
Tanmoy et al.,
12
(2010) studied the effect of adding Magnesium 
sulphate or Clonidine in epidural route along with Bupivacrine 0.5% in 
patients coming for lower abdominal and lower limb procedures. 
Group B -19 ml of 0.5%Bupivacaine + 1ml  MgSO4 (50mg) 
Group C - 19 ml of 0.5% Bupivacaine + 1ml of  Clonidine (150mg) 
Group A - 19 ml of 0.5% Bupivacaine + 1ml of Normal saline  
These groups were compared under the following criterias: 
 Time of onset of sensory block to T6 level. 
 Time to 2 segment regression. 
 Time for first epidural top up . 
 Sedation  etc. 
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They concluded that administration of epidural MgSO4 with 
bupivacaine produced predictable early onset of anaesthesia without any 
side effects and addition of clonidine prolongs analgesia and sedation. 
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AIM OF THE STUDY 
To compare the perioperative analgesic efficacy and haemo 
dynamicstability of epidural Buprenorphine and Dexmedetomidine with 
0.5%  Bupivacaine in lower limb orthopaedic surgeries. 
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MATERIALS AND  METHODS 
STUDY DESIGN:  Prospective, randomised, double blinded 
(subject/observer) study. 
STUDY SIZE:   80 Patients. 
RANDOMISATION :  By closed envelope method. 
INCLUSION CRITERIA  : 
• Age         : 16 years to 60 years. 
• ASA         : I & II. 
• Surgery  : Elective lower limb surgeries. 
• Only those who have given valid informed consent.  
• Weight :  50 kg   to  80 kg.  
EXCLUSION CRITERIA : 
• Not satisfying inclusion criteria. 
• Patients with short stature less than 145 cm and spine 
abnormalities. 
• Pregnant females. 
• Any contraindication to epidural anaesthesia like abnormal 
coagulation profile. 
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MATERIALS  REQUIRED: 
• 17 G Tuohy’s Epidural needle and 19 G catheter. 
• Drugs – 0.5% Bupivacaine for epidural anaesthesia, inj. 
Buprenorphine, inj. Dexmedetomidine, distilled water, inj. Ephedrine, 
inj. Atropine and other emergency drugs and 2% Lignocaine for local 
anaesthesia of the skin. 
• Monitors – ECG , NIBP , SPO2 .  
• 2 cc syringe and 5 cc syringe. 
• Betadine, spirit, gauze to disinfect the back. 
• 16G,18G intravenous cannula. 
• 0.9% Normal saline and Ringer lactate. 
PRE-OPERATIVE ASSESSMENT: 
In all patients, age, body weight and baseline vital parameters 
were recorded. History regarding previous anaesthesia, surgery and  
significant comorbid illness, medications and allergy was recorded. 
Complete physical examination and airway assessment were done. 
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In the preoperative period all patients were instructed about the 
benefits of epidural analgesia and also informed consent was obtained 
from all the study group patients. 
PREMEDICATION: 
All patients were premedicated with T.Alprazolam 0.25-0.5mg, at 
6 am on the day of surgery. inj. Ranitidine 50 mg i.v and inj. Emeset 
8mg i.v  was given 30 minutes  before surgery . 
MONITORS : 
Standard monitors like ECG, Non-invasive BP, and spO2 were 
connected to the patient.  
I VACCESS: 
Intravenous access was done using 16 or 18 Gauge venflon and 
10ml/kg intravenous crystalloid  was preloaded. 
EPIDURAL CATHETERISATION: 
With the patient in sitting position under strict aseptic 
precautions, with  17GTuohy’s epidural needle, L3-L4 interspace 
entered&  epidural space identified with loss of resistance technique. 
43 
 
Catheter was secured 3-5 cm inside the epidural space and a test dose of 
3 ml of  2% lignocaine was given after negative aspiration of blood and 
CSF. 
STUDY DRUG ADMINISTRATION : 
GROUP A :  12 ml of 0.5% Bupivacaine with 60µg 
Dexmedetomidinein 3ml distlled water. 
GROUP B :  12 ml of 0.5% Bupivacaine with 180µg  Buprenorphine  
in 3ml distilled water. 
GROUP C:  12 ml of 0.5% Bupivacaine plain with 3 ml of distilled 
water . 
The following observations were made in the patients : 
 Time to T-10 level sensory blockade in minutes. 
 Time to complete motor blockade in minutes. 
 Time to maximum sensory blockade in minutes. 
 Maximum sensory level attained. 
 Time to 2 segmental regression. 
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 Motor blockade was  assessed before the surgery by using 
Bromage Scale. 
 Sedation score  using Subjective Sedation Scale and sensory 
level  was assessed every 30 minutes during  intraoperative period  
and hourly postoperatively. 
If surgery gets prolonged beyond 3 hours or patient complaints of 
pain  or  level descends to T10, 6cc of 0.25% Bupivacaine was given  
Inj. Ephedrine 6mg was given when  MAP went < 70 mm of  Hg 
Intra-operatively vitals like ECG, Spo2, NIBP were continuously 
monitored 
 Postoperatively Patients were shifted to Post Anaesthesia Care 
Unit (PACU) for monitoring and quality of analgesia  assessed by using 
patient acceptance scale  
Rescue analgesia was  given on demand  with  inj.Diclofenac 75 
mg i.v, inj.Paracetamol 1g i.v and  0.125% Bupivacaine 6 mlalong with 
the test drug. 
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Any  adverse effects  like vomiting, nausea, pruritis, respiratory 
depression, headache,dry mouthand shivering were recorded both 
intraoperatively and  postoperatively. 
SUBJECTIVE SEDATION SCALE:                                                                       
Grade 0 : awake, conscious 
Grade 1 : calm, compose 
Grade 2 :  awake on command                          
Grade 3 :  awake on gentle tactile stimulus     
Grade 4 :  awake on vigorous shaking 
BROMAGE SCALE : 
0 :  no block  
1 :  inability to raise extended leg 
2 :  inability to flex knee      
3 :  inability to flex foot 
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OBSERVATIONS  AND  RESULTS 
STATISTICAL ANALYSIS : 
Data was analysed using SPSS software version 15.0 for windows 
Two sided independent  student' s  t  tests  and analysis of variance 
(ANOVA) with post hoc significance for  continuous data, Fisher's exact 
test and Chi-square test for qualitative  data were used. p<0.05 was 
considered as statistically significant and p<0.001 as very significant. 
DEMOGRAPHIC DATA: 
The three groups were comparable   with   respect to their age, 
weight, sex and ASA Physical status. There was no statistically 
significant difference among  groups in demographic profile. 
AGE : 
GROUP A B C P value 
Age in years 33.33 ± 7.73 33.83 ± 8.61 33.75 ± 6.28 0.967 
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WEIGHT : 
GROUP A B C P value 
Weight in kgs 62.7 ± 4.31 61.90 ± 3.91 63.75 ± 4.166 0.305 
 
SEX : 
GROUP A(%) B(%) C(%) P value 
Male 22(73.3%) 23(76.7%) 16(80%) 
0.860 
Female 8(26.7%) 7(23.3%) 4(20%) 
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DURATION OF SURGERY  : 
GROUP A B C P value 
Duration 
(in min) 
181 ± 32.73 190 ± 33.37 178 ± 23.46 0.344 
 
The mean duration of surgery was 181±32.73 min in group A, 
190±33.37 min in group B and 178±23.46 min in group C . There was 
no significant difference in the duration of surgery in all 3 groups 
(p>0.05) 
INITIAL BLOCK CHARACTERISTICS  : 
Time  
(in min) 
A B C P value 
t-T 10 10.60 ± 1.81 11.80 ± 1.49 18.70 ± 1.38 < 0.001 
t-max sensory 18.20 ± 2.39 20.40 ± 3.01 19.15 ± 1.75 .005 
t-motor 19.80 ± 3.42 30.03 ± 3.60 29.30 ± 2.69 .016 
 
The onset of analgesia at T 10 dermatomal level was 
significantly earlier in group A (10.60±1.81 min), as compared to that of 
group B (11.80±1.49  min) & group C (18.70±1.38 min) with p value 
<0.001  
Group A > Group B > Group C 
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Complete motor blockade was also much earlier in group A  
(19.80±3.42 min) than group B (30.03±3.60 min) & group C 
(29.30±2.69 min). There was significant difference between group A  
with group  B (p= 0.01)& group A  with  group C ( p =0.03), but not 
between group B & group C (p>0.05) 
Group A> Group B = Group C 
Maximum sensory level was attained earlier in group A 
(18.20±2.39 min) than that of group B (20.40±3.01min) & group C 
(19.15±1.75 min) and was significant p = 0.03 
Group A > Group C > Group B (spurious) 
as the level attained was higher in group B (T6) time taken was 
more than group C (T8-T10) and was spuriously prolonged than  
group C  
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MAXIMUM SENSORY LEVEL : 
Max sensory T4 T6 T8 T10 
A(%) 13 (43.3%) 13 (43.3%) 1 (3.3%) 0 
B(%) 7 (23.3%) 20 (66.7%) 3 (10%) 0 
C(%) 0 0 3 (15%) 17 (85%) 
 
Much higher sensory levels were attained with group A (T4) as 
compared to (T6) in group B and (T8-T10) in group C .Almost 87% of 
patients in group A and 90 % of  patients in group  B attained a level of  
T4-T6 
Group A = Group B > Group C 
Maximum sensory level 
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SEDATION SCORE  : 
Score A(%) B(%) C(%) 
0 0 2 (6.7%) 13 (65.5%) 
1 0 21 (70%) 7 (35.5%) 
2 14 (46.7%) 6 (20%) 0 
3 16 (53.3%) 1 (3.3%) 0 
4 0 0 0 
 
Mean Sedation scores were stastically higher in group A with p 
<0.001 than group B & group C .None of the patients in group A were 
awake during the surgery as compared to group C where more than half 
of the patients were wide awake. Almost all patients in group A were in 
deep sleep aroused only on calling or when gently tapped,as compared 
to nearly two third of patients in group B who were only calm and were  
awake 
Group A > Group B > Group C 
Sedation score 
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POSTOPERATIVE  BLOCKCHARACTERISTICS  : 
Time  
(in min) 
A B C P value 
t-2 segment 186.33 ± 27.23 199 ± 24.82 118.5 ± 18.99 <0.001 
t-post op 
analgesia 
410.33 ± 138.99 590.33 ± 140.18 286 ± 48.82 <0.001 
 
Quality of the blockade during regression was almost similar in 
group A and group B as the time to two segmental regression 
(186.33±27.23 min) and (199±24.82 min) respectively was not  
significant on statistical comparison (p = 0.118)  but they were much 
longer than group C (118.5±18.99 min) 
Group A = Group B > Group C 
Duration of post operative analgesia was significantly prolonged 
in group B  (590.33±140.18 min) and lasted almost 8-10 hrs 
postoperatively  as compared to  (410.33±138.99 min ) in group A and a 
much shorter duration of (286±48.82min) in group C. 
Group B > Group A > Group C 
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NUMBER OFPOST OP RESCUE ANALGESIA : ( in 24 hrs) 
No of rescue 
analgesia 
A (%) B (%) C (%) 
1 5 (16.7%) 27 (90%) 0 
2 16 (53.3%) 3 (10%) 5 (25%) 
3 9 (30%) 0 12 (60%) 
4 0 0 3 (15%) 
 
Duration of post operative analgesia was significantly prolonged  
in group B and the quality of analgesia was also good  in group B as 
90%  of  patients required  rescue analgesia only once in  24 hours as 
compared to only 16.7% in group A and  more than half of the patients 
in group A required rescue analgesia twice in 24 hours. duration of post 
operative  analgesia was  very short in group C as nearly three-fourth of 
the patients required more than 3 rescue analgesia in the first 24 hours . 
Group C > Group A > Group B 
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INTRA OP HEMODYNAMICS :  
Heart rate : 
 
Group A Group B Group C 
p  value 
mean Std.dev mean Std.dev mean Std.dev 
pr_ base 86.30 6.16 84.20 5.08 85.90 6.15 0.342 
pr_15 63.13 5.92 86.37 5.90 90.35 6.88 
p  value < 
0.001 
pr_30 62.93 5.43 79.87 4.65 85.00 5.49 
pr_60 62.90 6.09 78.00 8.06 89.35 11.60 
pr_90 62.83 6.64 76.57 4.72 76.85 10.21 
pr_120 62.87 6.22 74.90 4.10 75.10 7.77 
pr_150 62.93 6.44 75.20 3.95 70.05 8.67 
pr_180 63.20 6.50 75.70 5.42 73.05 7.83 
pr_240 62.17 5.61 76.67 6.27 71.40 6.92 
pr_6hr 62.77 4.74 79.70 8.44 72.20 7.94 
pr_8hr 62.53 5.08 81.37 9.81 70.65 9.18 
pr_10hr 62.00 5.72 80.80 9.30 72.40 8.08 
pr_12hr 62.63 6.63 77.67 7.77 79.70 8.06 
pr_16hr 62.73 5.88 81.37 8.09 70.20 6.23 
pr_20hr 62.17 5.39 79.50 6.81 72.00 6.46 
pr_24hr 72.33 6.70 79.87 5.53 71.35 7.98 
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Post hoc significance : 
PR – baseline 
Group A Group B p = 0.341 
 Group C 0.969 
Group B Group A 0.341 
 Group C 0.567 
PR – 15 min 
Group A Group B < 0.001 
 Group C < 0.001 
Group B Group A < 0.001 
 Group C 0.071 
PR – 30 min 
Group A Group B < 0.001 
 Group C < 0.001 
Group B Group A < 0.001 
 Group C 0.003 
PR – 60 min 
Group A Group B < 0.001 
 Group C < 0.001 
Group B Group A < 0.001 
 Group C <  0.001 
PR – 90 min 
Group A Group B < 0.001 
 Group C <0.001 
Group B Group A <0.001 
 Group C 0.990 
PR – 120 min 
Group A Group B <0.001 
 Group C <0.001 
Group B Group A <0.001 
 Group C 0.993 
PR – 150 min 
Group A Group B < 0.001 
 Group C < 0.001 
Group B Group A < 0.001 
 Group C 0.339 
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PR – 180 min 
Group A Group B < 0.001 
 Group C < 0.001 
Group B Group A < 0.001 
 Group C 0.613 
PR –240 min 
Group A Group B < 0.001 
 Group C < 0.001 
Group B Group A < 0.001 
 Group C 0.865 
PR – 6 hr 
Group A Group B < 0.001 
 Group C < 0.001 
Group B Group A < 0.001 
 Group C 0.613 
PR – 8 hr 
Group A Group B < 0.001 
 Group C < 0.001 
Group B Group A < 0.001 
 Group C 0.455 
PR –  10 hr 
Group A Group B < 0.001 
 Group C <0.001 
Group B Group A <0.001 
 Group C 0.990 
PR –  12hr 
Group A Group B < 0.001 
 Group C <0.001 
 Group B Group C 0.554 
 
Base line heart rates were comparable in all groups. There was 
significant reduction in heart rate in both group A and group B  between 
15 minutes to 90 minutes, but stabilized afterwards in group B and 
continued to be around 60/min in group A with a mean heart rate. Even 
in group A it never went less than 55/min. Reduction in heart rate  was 
more in  
Group A > Group B >Group C
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Requirement of ephedrine (in mgs)  : 
GROUP A B C P value 
Ephedrine 
used ( in mgs) 
13.4±6.99 3.4±5.15 4.2±3.92 <0.001 
Lowest  MAP  
(in mm of Hg) 
67.17±5.45 70.17±4.62 69.7±5.44 0.027 
 
Overall hemodynamics was stable in all 3 groups , as the Mean 
Arterial Pressure (MAP), never went below 60 mm of Hg throughout 
the perioperative period. But the requirement of  Inj.Ephedrine was  
significantly higher in group A (p<0.001), there was no stastistical 
difference in requirement of ephedrine between  group B and group C 
(p=0.877) 
Group A > Group B = Group C   
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The lowest MAP(mean arterial pressure) attained was  in group 
A  (67.17±5.45 mm of Hg) and  was  always on the  low  normal side   
in   group A  when compared to group B and group C where the MAP 
remained stable around (70.17±4.62 mm of Hg) and  (69.7±5.44 mm of 
Hg)  respectively. Thus the mean arterial pressure maintained at a 
better  level in group B 
GROUP B =GROUP C> GROUP A 
Lowest mean arterial pressure 
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PATIENT ACCEPTANCE  : 
Group 
0 
Not satisfied 
1 
satisfied 
2 
good 
3 
excellent 
p value 
A 2(8%) 12(40%) 14(46%) 2(8%)  
 
<0.001 
B 0 2(8%) 17(60%) 11(38%) 
C 5(20%) 11(54%) 4(16%) 0 
 
Patient acceptance was significantly better in group B, as 60% of 
patient rated is as good and 38% as excellent as compared to only 46% 
and 8%  in group B rated it as good and better respectively. 
Patient acceptance in group B was highly significant than group A 
(p<0.001) and group C (p< 0.001). therewas no significant difference 
between group A and group C in patient acceptance.(p = 0.0667) 
Group B>Group A =Group C 
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PATIENT  ACCEPTANCE  SCALE 
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ADVERSE EFFECTS : 
GROUP A B C P value 
HEADACHE 2(8%) 4(16%) 2(10%) 0.667 
NAUSEA 0(0%) 2(8%) 2(10%) 0.489 
VOMITING 0(0%) 2(8%) 2(10%) 0.489 
DRY MOUTH 3(10%) 0(0%) 0 0.109 
RESPIRATORY DEPRESSION 0(0%) 0(0%) 0 1.000 
SHIVERING 0 3(10%) 4(20%) 0.667 
 
Adverse effect profiles were comparable in all 3 groups. side 
effects like  nausea, vomiting, headache, dry mouth  and shivering was 
observed in all 3 groups and were statically insignificant with p>0.05, 
no respiratory depression or bradycardia i.e., PR< 50/min  was 
observed. 
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DISCUSSION 
Traditionally opioids are used as adjuvants in epidural and spinal 
anaesthesia. Alpha 2 agonist like Clonidine was also successfully used 
as adjuvant in the last decade as it produced excellent sedation and 
analgesia, but it also produced severe hypotension and bradycardia to 
overcome this newer alpha 2 agonist Dexmedetomidine was introduced 
and number of studies have been conducted successfully with 
Dexmedetomidine as adjuvant for  both spinal and epidural  blockade. 
Buprenorphine a long acting partial agonist, is a time honoured drug  
well  known for its prolonged  analgesic action but has a theoretical side 
effect of respiratory depression. Number of studies have also been 
conducted to elicit the safety and excellent analgesia produced by 
buprenorphine. Keeping in mind the side effect profile of both the drugs  
we  carefully designed a study to extract the maximum out of these 2 
drugs  as epidural adjuvants avoiding side effects. 
A  total of 80 patients who underwent elective lower 
limborthopaedic  surgeries  were randomly allocated in   3 groups.  
GROUP A  (30) : 12 ml of 0.5% Bupivacaine with 60µg 
Dexmedetomidine in 3ml distilled water  . 
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GROUP B   (30) : 12 ml of 0.5% Bupivacaine with 180µg  
Buprenorphine in 3ml distilled water . 
GROUP  C  (20)  : 12 ml of 0.5% Bupivacaine plain with 3 ml of 
distilled water . 
 
 The demographic profile in  all 3 groups were similar and there 
was no significant difference in Age, Sex,  ASA  physical status and 
Weight. Duration of surgery was around 3 hours in all 3 groups. 
ONSET  OF  BLOCK : 
Both Dexmedetomidine and Buprenorphine enabled an earlier 
onset and establishment of analgesia. Initial block characteristics were 
favourable in Dexmedetomidine than Buprenorphine group. Group A 
patients not only had an earlier onset of sensory block at T10  but  a 
much higher dermatome level of blockade  and complete motor 
blockade in a shorter duration. The addition of these two adjuvants 
promotes faster onset as compared to time of onset of sensory analgesia 
with Bupivacaine alone. 
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This  could be correlated  with a study by Sukhminder et al where 
they compared Dexmedetomidine1mcg/kg and Fentanyl 1mcg/kg along 
with  15 ml of 0.75%  epidural Ropivacaine in lower limb surgeries  in 
which the onset was significantly earlier than Fentanyl. In another study 
conducted by Sukhminder et al epidural Dexmedetomidine 2 mcg/kg 
was compared with clonidine 2 mcg/kg along with 17 ml of 0.75% 
Ropivacaine  in which also onset was earlier than Clonidine. 
SEDATION: 
Dexmedetomidine produced better sedation than Buprenorphine 
as most patients were deep asleep and arousable only on command or 
gentle tapping and without any respiratory depression. Patients in 
buprenorphine group remained calm and campose but were awake . 
This could be correlated to  
1.  Sukhminder et al., in 2 studies that Dexmedetomidine produced 
sedation of   grade 3 when compared with Clonidine and Fentanyl 
2. Vijay.G. anand et al in his study observed  that  caudal 
Dexmedetomidine  1mcg/kg along with 0.25% Bupivacaine  
produced excellent sedation in pediatrics  without respiratory 
depression 
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DURATION  OF  ANALGESIA  : 
Duration  of  analgesia  was  significantly  prolonged   in 
Buprenorphine  group  than  the  other  2  groups. Patients in 
Buprenorphine  groups did not require rescue analgesia for more than 8 
hours  post op  as compared  to 4-6 hours in Dexmedetomidine group 
and  2-3 hours in plain bupivacaine group . group B patients also 
required  lesser Number of postoperative  rescue  analgesia  and patient 
acceptance was also better with the  quality of analgesia produced in 
group B than group A and group C  
This could be correlated  with 
1. Kiran  agarwal  et al., observed that the duration  of  postoperative 
analgesia after injection of 0.125% Bupivacaine  with 0.075 mg 
of Buprenorphine was 690±24 minutes. 
2. Lanz et al ., observed that postoperative analgesia was prolonged 
to more than 9.6±3.2 hours in patients who received 0.3mg of 
epidural Buprenorphine , 7.5±4.2hours in patients who received 
0.15mg of Buprenorphine  
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HEMODYNAMIC  STABILITY : 
Overall hemodynamics were stable in all 3 groups , as MAP never 
went below 60 mm of  Hg  and  pulse rate  never went  less than  
50/min. But the requirement of  Ephedrine was significantly higher in  
Dexmedetomidine group and the blood pressure remained on the lower 
side in group A. Blood Pressure was stable in group B and C and 
requirement of  Ephedrine was also meagre. Hypotension was more with 
group A. 
This was against the observations in Sukhminder et al 
comparative efficacy of epidural Dexmedetomidine vs Fentanyl with 
Ropivacaine. As requirement of Vasopressors was not significantly 
higher when compared to  
Fentanyl, most probably due to the use of Ropivacaine which 
causes less hemodynamic changes than Bupivacaine . 
ADVERSE EFFECTS : 
None of the patients had respiratory difficulty warranting active 
management and the side effect profile in all 3 groups were not 
significant which correlated well with all other studies. 
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We observed a slightly higher incidence of  nausea and vomiting 
in group B, than group A and C. Dry mouth was  observed in 
Dexmedetomidine group and there was no shivering in group A.As the 
patients were catheterized urinary retention could not be assessed. 
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SUMMARY 
This double  blinded  prospective randomized controlled study 
was done to evaluate the Duration of Analgesia, Hemodynamic 
Stability, Sedation and Adverse effects of  Dexmedetomidine and 
Buprenorphine as adjuvants to  0.5%  epidural Bupivacaine in  patients 
undergoing lower limb orthopaedic surgeries. 
The following observations were made: 
1. Addition of Dexmedetomidine and Buprenorphine significantly 
shortens the onset of analgesia and increases the maximum level 
of blockade. 
2. Addition of Dexmedetomidine produces  arousable  intraoperative 
sedation than Buprenorphine. 
3. Addition of Buprenorphine prolongs the duration of analgesia 
post operatively and maintains better hemodynamic stability 
4. Quality of postoperative analgesia, number of rescue analgesia 
needed and patient acceptance was better with Buprenorphine. 
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5. There was no respiratory depression for both drugs and the 
incidence of side effects were statistically insignificant between 
groups. 
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CONCLUSION 
To conclude that 180µg of Buprenorphine seems to be a better 
adjuvant to epidural bupivacaine (0.5%) than 60µg Dexmedetomidine 
for postoperative analgesia. It has an excellent quality and a prolonged 
duration of postoperative analgesia with minimal side effects. The 
hemodynamic stability was well maintained with Buprenorphine. Even 
though 60µg Dexmedetomidine produced early onset of analgesia and 
good sedation, duration of  postoperative analgesia was shorter and 
fluctuations in hemodynamics were significantly higher. 
Overall experience with Buprenorphine was satisfactory as 
compared to Dexmedetomidinebecause of  its superior quality of  
analgesia, better hemodynamics and  patient comfort. 
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PATIENT CONSENT FORM 
Study title : Prospective randomised control study for comparing the 
efficacy of epidural buprenorphine and dexmedetomidine 
with 0.5% bupivacaine  in lower limborthopaedic surgeries. 
 
Study centre : Institute  of  Anaesthesiology  and  Critical Care, Rajiv  
Gandhi Govt.  Hospital, Chennai. 
 
Participant name :           Age:                         Sex:                                 
 
I.P.No: 
 
 
I confirm that i have understood the purpose of procedure for the above 
study .i have the opportunity to ask the question and all my questions and doubts 
have been answered to my satisfaction. 
I have been explained about the pitfall in the procedure.  I have been 
explained about the safety,advantage and disadvantage of the technique. 
I understand that my participation in the study is voluntary and that i am free 
to withdraw at anytime without giving any reason. 
I understand that investigator ,regulatory authorities and the ethics committee 
will not need my permission to look at my health records both in respect to current 
study and any further research that may be conducted in relation to it, even if i 
withdraw from the study . I understand that my identity will not be revealed in any 
information released to third parties or published , unless as required under the law . 
I agree not to restrict the use of any data or results that arise from the study . 
 
Time:          
Date:                                                 Signature / thumb impression  
Place:                                                            Patient name: 
 
Signature of the investigator: 
 
Name of the investigator: 
  
INFORMATION TO PARTICIPANTS 
Investigator   : Dr.S.VIJAY ANANDH . 
Name of the Participant   : 
Title   :  PROSPECTIVE RANDOMISED CONTROL 
STUDY FOR COMPARING THE EFFICACY 
OF EPIDURAL BUPRENORPHINE AND 
DEXMEDETOMIDINE WITH 0.5% 
BUPIVACAINE IN LOWER LIMB 
ORTHOPAEDIC  SURGERIES . 
You are invited to take part in this research study. We have got approval 
from the IEC. Your are asked to participate because you satisfy the eligibility 
criteria .We want to compare and study the safety and efficacy of epidural 
buprenorphine and dexmedetomidine with 0.5% bupivacaine in lower limb surgeries 
What is the Purpose of the Research: 
For orthopaedic surgeries , spinal/ epidural  anaesthesia with 0.5% 
bupivacaine alone is commonly given during anaesthesia which results in greater 
hemodynamic instability and short duration of pain relief . This study compares  the 
hemodynamic changes in different doses of spinal bupivacaine in combined spinal 
epidural technique. 
The Study Design: 
All the patients in the study will be divided into three groups.  Epidural 
catheter will be placed at L3-L4  in all patient . group A will receive 0.5% 
bupivacaine with dexmedetomidine,group B will receive 0.5% bupivacaine with 
buprenorphine,group C will receive 0.5% bupivacaine with distilled water . Time of 
onset of sensory and motor blockade noted.  Surgery  proceeded and all patients are 
shifted to PACU postoperatively for observation and postoperative pain relief 
management. 
  
Benefits: 
 In pure epidural technique there is less hemodynamic instability.  Moreover, 
the epidural catheter can be used for post-operative pain relief also. 
Discomforts and risks: 
Reduction in heart rate and blood pressure can occur. Sometimes vomiting 
can occur.  Reduction in heart rate is managed with inj. Atropine. Reduction in 
blood pressure is managed with inj. Ephedrine. Inj.Ondansetron is given pre-
operatively to control vomiting. 
This intervention has been shown to be well tolerated as shown by previous 
studies. And if you do not want to participate you will have alternative of setting the 
standard treatment and your safety is our prime concern. 
Time : 
Date : 
Place :                         Signature / Thumb Impression 
                                                                    Patient name  : 
 
Signature of the Investigator : ____________________________ 
 
Name of the Investigator  : ____________________________ 
 
 
  
PROFORMA 
Name:                                                  Age:          Sex:   Wt:          Ip No:     
Diagnosis:       ASA: 
Plan:        
 
Time to T10 blockade 
(in min) 
 Rescue analgesia 
Maximum sensory level   
Time to max sensory level                
(in min) 
 Adverse effects 
Time to complete motor blockade  
(in min) 
  
Time to 2 segmental regression      
(in min) 
  
Duration of sensory block   
Sedation score   
 
Sedation scale:     Bromagescale : 
Grade 0 :awake,conscious                               0 : no block 
Grade 1 :calm,compose                                    1 : inability to raise extended leg 
Grade 2 : awake on command                          2 : inability to flex knee      
Grade 3 : awake on gentle tactile stimulus    3 : inability to flex foot  
Grade 4 : awake on vigorous shaking 
 
 TIME BP PR Spo2     RR IVF DRUGS MAP 
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
 
 
MASTER CHART 
S. NO NAME AGE SEX DIAGNOSIS PROCEDURE WEIGHT ASA 
GROUP - A 
1. VENKATESH 18 M avascular necrosis Lt hip Lt THR 55 1 
2. RAVI 22 M # Rt SHAFT OF FEMUR ORIF 60 1 
3. MURUGAN 42 M # NECK OF  FEMUR HEMIARTHROPLASTY 58 2 
4. KATHAVARAYAN 40 M # SHAFT OF  FEMUR ORIF 68 1 
5. JITHENDRA 31 M # Lt   ACETABULUM ORIF 60 1 
6. KANNAN 31 M # BB Rt LEG ORIF 58 1 
7. VILLALAN 41 M OSTEOARTHRITIS Lt HIP Lt THR 60 1 
8. RAVI 39 M # SHAFT OF  FEMUR ORIF 62 1 
9. PARIMALA 30 F # NECK OF  FEMUR ORIF 60 1 
10. VISHNU 24 M # SHAFT OF  FEMUR HEMIARTHROPLASTY 66 1 
11. VIGNESH 23 M # Lt   ACETABULUM ORIF 70 1 
12. VIJAYAN 30 M # SHAFT OF  FEMUR ORIF 65 1 
13. PRABAKAR 29 M # SHAFT OF  FEMUR ORIF 66 1 
14. ESHWARI 45 F OSTEOARTHRITIS Lt HIP THR 70 1 
15. PRIYA 29 F # NECK OF  FEMUR THR 65 1 
16. SAMPATH  44 M # BB Rt LEG ORIF 66 1 
17. SELVAKUMAR 40 M avascular necrosis Lt hip THR 62 1 
18 BABLOO GUPTA 28 M # Lt   ACETABULUM ORIF 60 1 
19. JYOTHI 33 F # SHAFT OF  FEMUR ORIF 66 1 
20. ALBERT 34 M # MEDIAL CONDYLE FEMUR  ORIF 56 1 
21. SURESH 35 M OSTEOARTHRITIS Rt HIP THR 70 1 
22 AMBIKA 45 F # NECK OF  FEMUR HEMIARTHROPLASTY 65 1 
23. RAMANUJAM 25 M # BB Rt LEG ORIF 66 1 
24. PRAKASH 33 M OSTEOARTHRITIS Lt hip THR 62 1 
25. PUSHPA 34 F # BB Rt LEG ORIF 60 1 
26. HARIKRISHNAN 28 M # NECK OF  FEMUR HEMIARTHROPLASTY 58 2 
27. MAYAVATHI 45 F # SHAFT OF  FEMUR ORIF 68 1 
28. RAMESH 44 M #BB Lt LEG ORIF 60 1 
29. SANJAY 24 M # BB Rt LEG ORIF 58 1 
30. CHITRA 34 F # TIBIAL PLATEAU  BICOLUMNAR PLATING 60 1 
MASTER CHART 
S. NO NAME AGE SEX DIAGNOSIS PROCEDURE WEIGHT ASA 
GROUP - B 
1. RAVI 42 M #NON UNION TIBIA ILIZAROV'S FIXATION  65 1 
2. RAMESH 34 M # SHAFT OF FEMUR ORIF 56 1 
3. BAJRANG CHONDI 40 M #SHAFT OF FEMUR,PATELLA ORIF & WIRING 60 1 
4. KRISHNAN 52 M # BB Lt LEG ORIF 60 2 
5. ESTHER 48 F # BB Lt LEG ORIF 60 1 
6. MOHANA 35 F # SHAFT OF FEMUR ORIF 58 1 
7. ASPADHAM 20 M # PROXIMAL TIBIA ORIF 65 1 
8. VENKATESAN 28 M #BB Rt LEG ORIF 68 1 
9. VENU 45 M # TROCHANTER Lt FEMUR DHS 62 1 
10. SIVAKUMAR 27 M #SHAFT OF FEMUR,PATELLA ORIF & WIRING 58 1 
11. SUNDAR  29 M # SHAFT OF FEMUR ORIF 60 1 
12. BABU 41 M # SHAFT OF FEMUR ORIF 70 1 
13. SUDHAKAR 26 M #BB Rt LEG ORIF 64 1 
14. MURUGAN 26 M # DISTAL TIBIA ORIF 65 1 
15. PONNAN 35 M SEGMENTAL # TIBIA ILIZAROV'S FIXATION  56 1 
16. SURESH 18 M #SHAFT OF FEMUR,PATELLA ORIF & WIRING 64 1 
17. CHANDRAN 24 M #MEDIAL MALLEOLUS TIBIA ORIF 60 1 
18. CHELLAMUTHU 27 M # PROXIMAL TIBIA ORIF 70 1 
19. CHINNADURAI 27 M #NON UNION TIBIA ILIZAROV'S FIXATION  62 1 
20. RAJENDRAN 34 M #BB Rt LEG ORIF 64 1 
21. MANJULA 33 F # SHAFT OF FEMUR ORIF 60 1 
22. KUMAR 40 M # SHAFT OF FEMUR ORIF 60 2 
23. LAKSHMI 41 F #BB Rt LEG ORIF 60 1 
24. KUPPAMAL 45 F # DISTAL TIBIA ORIF 58 1 
25. VASANTH 28 M # TROCHANTER Lt FEMUR DHS 62 1 
26. RAJALAKSHMI 33 F #SHAFT OF FEMUR,PATELLA ORIF & WIRING 58 1 
27. MAHESH 26 M # SHAFT OF FEMUR ORIF 60 1 
28. RAJESHWARI 44 F # SHAFT OF FEMUR ORIF 70 1 
29. MANIKANDAN 28 M OSTEOARTHRITIS Lt HIP Lt THR 60 1 
30. MUTHU 39 M # SHAFT OF  FEMUR ORIF 62 1 
MASTER CHART 
S. NO NAME AGE SEX DIAGNOSIS PROCEDURE WEIGHT ASA 
GROUP - C 
1. VARATHARAJAN 40 M # SHAFT OF  FEMUR ORIF 68 1 
2. ARUN 31 M # Lt   ACETABULUM ORIF 60 1 
3. VANITHA 31 M # BB Rt LEG ORIF 58 1 
4. VIJAY 41 M # BB Rt LEG ORIF 60 1 
5. SELVI 39 M # SHAFT OF  FEMUR ORIF 62 1 
6. ANANDH 30 F # NECK OF  FEMUR ORIF 60 1 
7. PUNITHA 24 M # SHAFT OF  FEMUR HEMIARTHROPLASTY 66 1 
8. VASUDEVAN 23 M # Lt   ACETABULUM ORIF 70 1 
9. SUBBHARAO 30 M # SHAFT OF  FEMUR ORIF 65 1 
10. MITHUN 29 M # SHAFT OF  FEMUR ORIF 66 1 
11. BASKAR 45 F #BB Rt LEG ORIF 70 1 
12 ESHWARAIAH 29 F # DISTAL TIBIA ORIF 65 1 
13. BAKKIYARAJ 44 M # BB Rt LEG ORIF 66 1 
14. SUNIL KUMAR 40 M #MEDIAL MALLEOLUS TIBIA ORIF 62 1 
15. SENTHIL 28 M # Lt   ACETABULUM ORIF 60 1 
16. SABAPATHY 33 F # SHAFT OF  FEMUR ORIF 66 1 
17. YESHWANTH 34 M # MEDIAL CONDYLE FEMUR  ORIF 56 1 
18. SARAVANAN 35 M # BB Rt LEG ORIF 70 1 
19. MOHAMED ALI 38 M #BB Lt LEG on EXFIX EXCHANGE NAILING 65 1 
20. SANTHOSH  31 M INFECTED IMPLANT  TIBIA IMPLANT REMOVAL 60 1 
 
 
  
MASTER CHART 
S. 
No 
t- 
T10 
t- 
sensory 
t-
motor 
max 
sensory 
t-2 
segment 
regression 
Duration 
of 
analgesia 
Sedation 
score 
Ephedrine 
used 
Lowest 
MAP 
Duration 
of 
surgery 
Intra op 
EPIDURA
L top up 
post 
op 
rescue 
Patient 
acceptance 
score 
GROUP - A 
1. 13 20 26 T6 160 250 2 18 67 190 0 2 1 
2. 13 22 24 T6 180 300 3 18 66 260 0 2 3 
3. 11 20 22 T6 150 420 3 0 90 140 0 2 2 
4. 11 18 20 T4 180 540 2 12 69 180 0 2 2 
5. 12 20 24 T6 160 275 2 0 76 180 0 3 1 
6. 14 20 25 T6 150 335 3 6 65 120 0 2 1 
7. 12 20 24 T6 240 710 2 6 69 180 0 1 2 
8. 12 19 18 T4 200 490 3 12 67 190 0 2 2 
9. 9 18 20 T4 210 530 3 18 63 180 0 2 3 
10. 12 18 18 T8 200 600 2 24 69 190 0 1 2 
11. 11 19 20 T6 170 660 2 6 62 200 0 1 2 
12. 9 18 18 T5 180 440 3 24 61 200 0 3 2 
13. 12 20 18 T4 180 420 3 30 57 240 0 2 1 
14. 10 16 18 T5 210 380 2 12 64 150 0 2 1 
15. 8 15 18 T4 150 180 3 18 65 160 0 3 1 
16. 9 14 16 T6 210 300 3 18 69 170 0 2 1 
17. 9 14 15 T4 210 380 3 18 66 150 0 3 2 
18. 8 18 15 T4 200 510 2 12 69 230 0 2 0 
19. 9 20 20 T4 180 660 3 18 67 160 0 1 1 
20. 10 22 18 T4 210 280 2 6 67 160 0 3 2 
21. 10 16 18 T5 210 380 2 12 64 180 0 3 2 
22. 8 15 18 T4 150 180 3 18 65 120 0 3 1 
23. 9 14 16 T6 210 300 3 18 69 180 0 2 2 
24. 9 14 15 T4 210 380 3 18 66 210 0 3 2 
25. 8 18 15 T4 200 360 2 12 69 240 0 2 1 
26. 11 20 22 T6 150 420 3 12 65 180 0 2 0 
27. 11 18 20 T4 180 480 2 12 69 150 0 2 2 
28. 12 20 24 T6 160 275 2 12 66 170 0 3 1 
29. 14 20 25 T6 150 335 3 6 65 190 0 2 1 
30. 12 20 24 T6 240 540 2 6 69 180 0 1 2 
MASTER CHART 
S. 
No 
t- 
T10 
t- 
sensory 
t-
motor 
max 
sensory 
t-2 
segment 
regression 
Duration 
of 
analgesia 
Sedation 
score 
Ephedrine 
used 
Lowest 
MAP 
Duration 
of 
surgery 
Intra op 
EPIDURA
L top up 
post 
op 
rescue 
Patient 
acceptance 
score 
GROUP - B 
1. 14 18 20 T6 200 660 0 6 69 240 0 1 2 
2. 10 20 20 T6 210 360 2 6 67 210 0 2 2 
3. 10 15 18 T4 200 600 1 18 64 220 0 1 2 
4. 12 22 25 T4 220 720 2 0 72 220 0 1 3 
5. 13 20 24 T6 180 540 1 6 69 190 0 1 3 
6. 13 25 22 T6 240 600 2 6 68 180 0 1 2 
7. 15 20 25 T6 200 360 1 0 70 270 0 1 2 
8. 11 18 220 T6 180 480 1 0 72 240 0 1 3 
9. 9 18 18 T4 200 720 1 6 64 150 0 1 2 
10. 13 24 28 T6 180 480 1 0 72 180 0 1 3 
11. 13 25 25 T6 200 680 1 0 74 180 0 1 2 
12. 12 20 25 T8 160 780 1 0 70 200 0 1 2 
13. 12 24 28 T6 180 300 1 0 72 180 0 2 3 
14. 10 18 24 T6 180 450 1 0 74 120 0 1 3 
15. 11 18 28 T8 200 600 1 0 71 170 0 1 3 
16. 12 18 24 T6 240 720 1 0 70 210 0 2 3 
17. 13 20 28 T6 180 360 1 0 84 120 0 1 2 
18. 10 18 22 T6 240 480 1 0 74 180 0 1 1 
19. 10 18 22 T6 210 740 1 0 76 150 0 1 2 
20. 12 25 28 T6 150 760 0 0 82 210 0 1 2 
21. 10 15 18 T4 200 600 1 18 64 220 0 1 1 
22. 12 22 25 T4 220 720 2 0 72 220 0 1 2 
23. 13 20 24 T6 180 540 1 6 69 190 0 1 2 
24. 13 25 22 T6 240 600 2 6 68 180 0 1 3 
25. 9 18 18 T4 200 720 1 6 64 150 0 1 2 
26. 13 24 28 T6 180 480 1 0 72 180 0 1 3 
27. 13 25 25 T6 200 680 1 0 74 180 0 1 2 
28. 12 20 25 T8 160 780 1 0 70 200 0 1 2 
29. 12 20 24 T6 240 710 2 6 69 180 0 1 3 
30. 12 19 18 T4 200 490 3 12 67 190 0 1 2 
MASTER CHART 
S. 
No 
t- 
T10 
t- 
sensory 
t-
motor 
max 
sensory 
t-2 
segment 
regression 
Duration 
of 
analgesia 
Sedation 
score 
Ephedrine 
used 
Lowest 
MAP 
Duration 
of 
surgery 
Intra op 
EPIDURA
L top up 
post 
op 
rescue 
Patient 
acceptance 
score 
GROUP - C 
1. 19 19 32 T10 140 240 0 6 64 180 1 3 2 
2. 18 18 30 T10 120 300 1 0 72 190 2 4 1 
3. 20 20 28 T10 120 280 1 6 65 240 2 3 1 
4. 19 19 32 T10 100 320 0 6 68 180 1 4 1 
5. 19 19 30 T10 140 280 0 6 68 180 1 4 0 
6. 17 17 25 T10 150 300 0 12 62 180 1 3 0 
7. 18 20 28 T8 100 420 0 6 69 150 0 2 0 
8. 19 19 32 T10 110 280 1 6 64 180 0 3 2 
9. 20 20 29 T10 120 240 0 0 70 180 1 3 2 
10. 21 21 34 T10 140 300 0 0 82 200 1 3 1 
11. 16 16 26 T10 100 360 0 6 68 180 1 3 1 
12. 20 24 32 T8 100 300 1 6 66 190 1 3 1 
13. 18 18 25 T10 90 210 1 0 74 150 0 3 1 
14. 21 21 32 T10 120 240 1 0 80 180 1 3 2 
15. 20 20 31 T10 140 270 0 6 66 180 0 2 1 
16. 18 18 26 T10 150 210 0 12 64 200 2 3 1 
17. 18 18 28 T10 110 280 0 6 68 180 1 2 1 
18. 17 17 26 T10 120 320 0 0 76 120 0 3 1 
19. 19 19 30 T10 100 300 0 0 72 170 1 2 0 
20. 17 20 30 T8 100 270 1 0 74 160 0 2 0 
 
 
 
 
 
MASTER CHART 
S.No 
Base 
Line 
15  
min 
30 
min 
60  
min 
90 
min 
120 
min 
150 
min 
180 
min 
240 
min 
6 hrs 8 hrs 
10 
hrs 
12 
hrs 
16 
hrs 
20 
hrs 
24 
hrs 
PULSE  RATE – GROUP A 
1. 81 58 56 56 57 58 59 59 58 58 56 59 57 58 60 67 
2. 91 59 61 60 60 61 62 62 59 63 61 61 62 60 60 76 
3. 84 65 64 67 66 65 68 65 69 65 65 66 66 67 64 66 
4. 88 58 56 57 57 55 59 57 58 57 56 57 58 58 59 78 
5. 88 64 64 63 63 62 61 66 63 60 62 63 61 60 63 74 
6. 84 55 58 58 47 49 54 55 49 57 56 52 55 55 54 70 
7. 77 66 66 65 67 67 64 64 63 63 63 63 63 64 62 78 
8. 78 66 66 65 67 66 63 66 67 66 65 66 65 67 68 66 
9. 79 59 58 57 60 58 57 58 57 59 57 56 58 57 58 64 
10. 90 58 58 59 60 59 59 58 57 59 59 59 58 59 59 65 
11. 94 67 66 69 70 71 73 69 68 68 69 69 69 68 67 78 
12. 88 66 66 67 68 68 67 67 66 68 66 66 67 67 66 85 
13. 81 77 76 76 75 74 76 79 71 69 72 71 77 76 75 80 
14. 84 70 70 71 71 71 72 71 70 71 70 72 73 71 71 74 
15. 81 67 66 68 69 68 68 69 70 69 69 68 69 69 65 69 
16. 87 54 55 49 49 54 52 52 53 54 55 49 48 55 53 68 
17. 90 58 60 59 59 58 58 57 59 59 58 57 58 58 56 64 
18. 79 57 60 59 58 59 56 57 59 58 59 58 58 58 58 62 
19. 76 59 59 60 58 59 59 57 60 63 59 58 59 60 59 78 
20. 82 67 63 63 60 60 59 62 61 58 62 60 60 61 61 76 
21. 86 66 63 62 61 60 58 60 62 60 64 62 58 61 60 76 
22. 87 59 59 58 58 60 61 61 62 62 59 60 61 62 60 66 
23. 90 68 69 66 67 69 66 67 66 69 66 65 70 68 62 68 
24. 96 67 66 66 65 65 65 66 59 64 64 64 62 60 61 78 
25. 93 57 59 59 60 60 60 61 60 61 61 58 58 56 59 72 
26. 98 59 58 57 60 58 57 58 57 59 57 56 58 57 58 64 
27. 84 58 58 59 60 59 59 58 57 59 59 59 58 59 59 65 
28. 89 67 66 69 70 71 73 69 68 68 69 69 69 68 67 78 
29. 90 66 66 67 68 68 67 67 66 68 66 66 67 67 66 85 
30. 88 77 76 76 75 74 76 79 71 69 72 71 77 76 75 80 
MASTER CHART 
S.No 
Base 
Line 
15  
min 
30 
min 
60  
min 
90 
min 
120 
min 
150 
min 
180 
min 
240 
min 
6 hrs 8 hrs 
10 
hrs 
12 
hrs 
16 
hrs 
20 
hrs 
24 
hrs 
PULSE  RATE – GROUP B 
1. 81 100 78 70 69 77 72 73 74 77 83 84 83 83 81 84 
2. 102 91 87 79 80 81 82 83 83 90 98 89 85 81 86 82 
3. 99 84 78 76 73 75 78 82 81 88 89 83 82 72 77 78 
4. 97 88 83 76 80 80 80 78 72 77 79 79 79 76 72 73 
5. 94 88 78 78 85 77 72 72 69 71 71 75 80 81 74 79 
6. 91 84 76 74 75 75 74 70 73 75 78 78 76 75 73 76 
7. 85 77 72 79 76 77 75 76 82 84 92 92 81 79 88 81 
8. 82 78 72 76 77 72 71 76 79 87 83 82 84 79 78 72 
9. 85 79 79 71 71 70 78 72 78 84 92 85 83 78 81 81 
10. 82 90 77 83 79 79 79 74 84 85 84 85 83 82 86 83 
11. 96 94 79 82 75 72 76 76 76 79 79 77 74 79 81 86 
12. 92 88 83 79 80 81 74 84 86 90 90 91 57 85 88 84 
13. 105 81 75 71 78 76 75 78 76 75 79 82 80 80 79 78 
14. 92 84 77 76 71 77 74 77 78 88 90 89 78 82 80 81 
15. 91 81 77 75 74 74 75 75 78 85 86 84 81 80 80 84 
16. 96 87 71 71 70 73 78 84 80 79 82 81 80 78 78 77 
17. 94 90 77 70 74 74 77 80 80 82 88 91 84 84 82 85 
18. 89 79 81 75 77 76 73 70 69 76 83 82 72 74 75 80 
19. 96 76 85 76 71 72 72 82 77 73 76 79 85 77 79 80 
20. 88 82 76 67 75 74 70 75 74 71 71 67 76 78 73 74 
21. 87 86 85 84 79 74 71 69 69 74 74 65 78 79 74 87 
22. 92 87 86 79 76 77 70 75 83 91 91 89 81 81 82 86 
23. 103 90 76 74 71 77 78 82 82 97 95 92 81 82 78 88 
24. 111 96 80 76 75 75 75 77 76 77 79 92 79 77 77 76 
25. 99 93 85 78 74 78 75 78 84 81 81 83 80 76 79 83 
26. 78 92 85 76 76 72 74 65 60 55 52 60 62 74 69 66 
27. 82 84 83 78 79 82 78 74 74 75 78 79 80 86 66 68 
28. 82 88 83 87 84 64 66 81 86 83 84 82 76 87 80 87 
29. 80 82 85 95 86 67 79 62 65 67 60 56 52 106 87 81 
30. 80 92 87 109 87 69 85 71 72 75 74 71 78 110 102 76 
MASTER CHART 
S.No 
Base 
Line 
15  
min 
30 
min 
60  
min 
90 
min 
120 
min 
150 
min 
180 
min 
240 
min 
6 hrs 8 hrs 
10 
hrs 
12 
hrs 
16 
hrs 
20 
hrs 
24 
hrs 
PULSE  RATE – GROUP C 
1. 82 93 91 79 70 71 87 66 64 68 60 56 84 86 80 86 
2. 82 102 91 108 66 74 75 71 76 75 74 72 80 66 69 69 
3. 77 87 86 79 64 74 70 74 75 81 82 85 84 64 62 60 
4. 82 84 82 85 68 65 68 64 68 60 56 84 89 71 76 75 
5. 84 97 93 86 69 69 69 75 68 69 64 68 71 74 75 81 
6. 81 93 88 103 77 70 63 74 75 81 82 85 84 64 68 60 
7. 85 85 86 92 90 81 62 64 68 60 56 84 89 75 68 69 
8. 78 96 80 90 73 74 64 75 68 69 64 68 71 72 75 71 
9. 82 92 93 101 69 66 67 84 86 74 76 67 75 70 79 78 
10. 73 86 83 86 66 68 65 85 80 76 84 72 78 65 60 55 
11. 76 84 77 87 80 87 64 84 86 88 89 80 88 74 74 75 
12. 82 101 85 106 87 81 62 69 69 60 68 62 79 81 86 83 
13. 73 100 82 110 102 76 75 62 60 70 74 72 74 62 65 67 
14. 78 90 74 89 88 90 85 70 64 75 70 74 71 71 72 75 
15. 78 76 86 86 80 86 84 70 71 87 66 64 84 70 74 75 
16. 79 80 88 85 87 78 68 66 74 75 71 76 89 66 64 68 
17. 81 89 90 87 85 77 71 64 74 70 74 75 71 71 76 75 
18. 84 93 88 74 75 81 82 85 65 68 64 68 95 60 68 62 
19. 75 90 78 64 68 60 56 84 69 69 75 68 67 70 74 72 
20. 81 89 79 90 73 74 64 75 68 69 64 68 71 72 75 71 
 
